IL150801A0 - The use of copolymer 1 and related peptides and polypeptides for protecting central nervous system cells from glutamate toxicity - Google Patents
The use of copolymer 1 and related peptides and polypeptides for protecting central nervous system cells from glutamate toxicityInfo
- Publication number
- IL150801A0 IL150801A0 IL15080101A IL15080101A IL150801A0 IL 150801 A0 IL150801 A0 IL 150801A0 IL 15080101 A IL15080101 A IL 15080101A IL 15080101 A IL15080101 A IL 15080101A IL 150801 A0 IL150801 A0 IL 150801A0
- Authority
- IL
- Israel
- Prior art keywords
- nervous system
- cop
- polypeptide
- polypeptides
- copolymer
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 10
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 210000003169 central nervous system Anatomy 0.000 title abstract 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 title 1
- 229920001577 copolymer Polymers 0.000 title 1
- 229930195712 glutamate Natural products 0.000 title 1
- 230000001988 toxicity Effects 0.000 title 1
- 231100000419 toxicity Toxicity 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 210000005036 nerve Anatomy 0.000 abstract 2
- 210000000653 nervous system Anatomy 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 2
- 230000008929 regeneration Effects 0.000 abstract 2
- 238000011069 regeneration method Methods 0.000 abstract 2
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46432—Nervous system antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Marine Sciences & Fisheries (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20979900P | 2000-06-07 | 2000-06-07 | |
US62021600A | 2000-07-20 | 2000-07-20 | |
PCT/US2001/002118 WO2001093893A2 (en) | 2000-06-07 | 2001-01-22 | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
IL150801A0 true IL150801A0 (en) | 2003-02-12 |
Family
ID=26904524
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15080101A IL150801A0 (en) | 2000-06-07 | 2001-01-22 | The use of copolymer 1 and related peptides and polypeptides for protecting central nervous system cells from glutamate toxicity |
IL150801A IL150801A (en) | 2000-06-07 | 2002-07-18 | Use of Copolymer 1 and related peptides and polypeptides and T cells activated by them for the preparation of preparations for the treatment of a disease caused or aggravated by glutamate toxicity |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL150801A IL150801A (en) | 2000-06-07 | 2002-07-18 | Use of Copolymer 1 and related peptides and polypeptides and T cells activated by them for the preparation of preparations for the treatment of a disease caused or aggravated by glutamate toxicity |
Country Status (17)
Country | Link |
---|---|
US (1) | US20020037848A1 (zh) |
EP (1) | EP1294390B1 (zh) |
JP (1) | JP4328090B2 (zh) |
KR (1) | KR20030007397A (zh) |
CN (1) | CN100438906C (zh) |
AT (1) | ATE314860T1 (zh) |
AU (1) | AU783031B2 (zh) |
CA (1) | CA2398277C (zh) |
CY (1) | CY1105263T1 (zh) |
DE (1) | DE60116467T2 (zh) |
DK (1) | DK1294390T3 (zh) |
ES (1) | ES2256200T3 (zh) |
HK (1) | HK1058892A1 (zh) |
IL (2) | IL150801A0 (zh) |
MX (1) | MXPA02007109A (zh) |
NZ (1) | NZ520282A (zh) |
WO (1) | WO2001093893A2 (zh) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1098902A4 (en) | 1998-07-23 | 2002-07-24 | Yeda Res & Dev | TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES |
ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
PL363431A1 (en) * | 2000-06-05 | 2004-11-15 | Teva Pharmaceuticals Industries, Ltd. | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
ES2349033T3 (es) | 2001-12-04 | 2010-12-22 | Teva Pharmaceutical Industries, Ltd. | Procedimientos para la medida de la actividad del acetato de glatiramer. |
PT1429800E (pt) * | 2001-12-06 | 2009-04-27 | Yeda Res & Dev | Vacina e sua utilização para tratamento de esclerose lateral amiotrófica |
CA2512735C (en) * | 2003-01-07 | 2016-03-08 | Yeda Research And Development Co. Ltd. | Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
WO2005030955A1 (ja) * | 2003-09-29 | 2005-04-07 | Chugai Seiyaku Kabushiki Kaisha | Nk細胞に発現するタンパク質 |
CA2540890A1 (en) * | 2003-10-03 | 2005-04-14 | Bayhill Therapeutics, Inc. | Treatment of demyelinating autoimmune disease with modified ordered peptides |
AU2004288654B2 (en) | 2003-11-12 | 2009-12-03 | Yeda Research And Development Co. Ltd. | Vaccine and method for treatment of neurodegenerative diseases |
SI1701730T1 (sl) * | 2003-12-09 | 2014-01-31 | Yeda Research And Development Co. Ltd. The Weizmann Institute Of Science | Postopek in cepivo, ki obsega kopolimer 1 za zdravljenje psihiatriäśnih motenj |
JP5495490B2 (ja) | 2004-05-07 | 2014-05-21 | アレス トレーディング エスエイ | ランダム共重合体を用いる疾患の治療方法 |
CN101166754B (zh) | 2004-09-09 | 2014-04-23 | 特瓦制药工业有限公司 | 使用纯化的氢溴酸制备多肽混合物的方法 |
EP1827108B1 (en) * | 2004-11-29 | 2015-04-08 | Yeda Research And Development Co., Ltd. | Induction of neurogenesis and stem cell therapy in combination with copolymer 1 |
US8378072B2 (en) | 2006-04-13 | 2013-02-19 | Declion Pharmaceuticals, Inc. | Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability |
US8193147B2 (en) | 2007-09-24 | 2012-06-05 | Hadasit Medical Research Services & Development Ltd. | Use of copolymer 1 for treatment of muscular dystrophy |
KR20170075026A (ko) | 2007-10-16 | 2017-06-30 | 펩팀문, 인코포레이티드 | 에피토프의 지정 확장에 의해 지정 서열 중합체 조성물을 포함하는 백신을 설계하고 제조하는 방법 |
WO2009063459A2 (en) * | 2007-11-13 | 2009-05-22 | Yeda Research And Development Co. Ltd | Synthetic peptide copolymers for treatment of neurodevelopmental disorders |
LT3199172T (lt) | 2009-08-20 | 2018-10-25 | Yeda Research And Development Co., Ltd. | Dozavimo režimas, skirtas išsėtinei sklerozei |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
US8377885B2 (en) | 2010-01-04 | 2013-02-19 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
ES2699692T3 (es) | 2010-01-04 | 2019-02-12 | Mapi Pharma Ltd | Sistema de depósito que comprende acetato de glatiramer |
US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
PT2627669T (pt) | 2010-10-11 | 2016-11-24 | Teva Pharma | Biomarcadores de citocina como biomarcadores preditivos de resposta clínica para acetato de glatirâmero |
WO2012143924A1 (en) | 2011-04-21 | 2012-10-26 | Mapi Pharma Ltd. | Random pentapolymer for treatment of autoimmune diseases |
WO2013055683A1 (en) | 2011-10-10 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
EP3320914B1 (en) | 2012-09-10 | 2020-12-30 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | T-helper 1 adjuvant for treating amyotrophic lateral sclerosis |
WO2018178973A1 (en) | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
KR20230128606A (ko) * | 2022-02-28 | 2023-09-05 | 경상국립대학교산학협력단 | 티로신을 유효성분으로 함유하는 알츠하이머병의 예방, 개선 또는 치료용 조성물 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL36670A (en) * | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
US5800808A (en) * | 1994-05-24 | 1998-09-01 | Veda Research And Development Co., Ltd. | Copolymer-1 improvements in compositions of copolymers |
EP1054880A1 (en) * | 1998-02-13 | 2000-11-29 | Autoimmune, Inc. | TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES |
-
2001
- 2001-01-22 NZ NZ520282A patent/NZ520282A/en not_active IP Right Cessation
- 2001-01-22 DE DE60116467T patent/DE60116467T2/de not_active Expired - Lifetime
- 2001-01-22 IL IL15080101A patent/IL150801A0/xx active IP Right Grant
- 2001-01-22 WO PCT/US2001/002118 patent/WO2001093893A2/en active IP Right Grant
- 2001-01-22 CN CNB018065910A patent/CN100438906C/zh not_active Expired - Lifetime
- 2001-01-22 KR KR1020027009275A patent/KR20030007397A/ko not_active Application Discontinuation
- 2001-01-22 AU AU34518/01A patent/AU783031B2/en not_active Expired
- 2001-01-22 CA CA2398277A patent/CA2398277C/en not_active Expired - Lifetime
- 2001-01-22 JP JP2002501464A patent/JP4328090B2/ja not_active Expired - Fee Related
- 2001-01-22 EP EP01906632A patent/EP1294390B1/en not_active Expired - Lifetime
- 2001-01-22 US US09/765,301 patent/US20020037848A1/en not_active Abandoned
- 2001-01-22 ES ES01906632T patent/ES2256200T3/es not_active Expired - Lifetime
- 2001-01-22 MX MXPA02007109A patent/MXPA02007109A/es active IP Right Grant
- 2001-01-22 DK DK01906632T patent/DK1294390T3/da active
- 2001-01-22 AT AT01906632T patent/ATE314860T1/de active
-
2002
- 2002-07-18 IL IL150801A patent/IL150801A/en unknown
-
2004
- 2004-03-05 HK HK04101665.8A patent/HK1058892A1/xx not_active IP Right Cessation
-
2006
- 2006-02-16 CY CY20061100219T patent/CY1105263T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU3451801A (en) | 2001-12-17 |
WO2001093893A2 (en) | 2001-12-13 |
ATE314860T1 (de) | 2006-02-15 |
EP1294390A2 (en) | 2003-03-26 |
EP1294390B1 (en) | 2006-01-04 |
HK1058892A1 (en) | 2004-06-11 |
CN1462190A (zh) | 2003-12-17 |
CY1105263T1 (el) | 2010-03-03 |
KR20030007397A (ko) | 2003-01-23 |
JP2004507460A (ja) | 2004-03-11 |
CN100438906C (zh) | 2008-12-03 |
DE60116467D1 (de) | 2006-03-30 |
DE60116467T2 (de) | 2006-11-02 |
IL150801A (en) | 2007-10-31 |
AU783031B2 (en) | 2005-09-15 |
MXPA02007109A (es) | 2002-12-13 |
JP4328090B2 (ja) | 2009-09-09 |
NZ520282A (en) | 2004-09-24 |
WO2001093893A3 (en) | 2002-04-04 |
DK1294390T3 (da) | 2006-04-03 |
CA2398277C (en) | 2013-09-03 |
ES2256200T3 (es) | 2006-07-16 |
US20020037848A1 (en) | 2002-03-28 |
CA2398277A1 (en) | 2001-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL150801A0 (en) | The use of copolymer 1 and related peptides and polypeptides for protecting central nervous system cells from glutamate toxicity | |
IL150800A0 (en) | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy | |
WO1999060021A3 (en) | Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system | |
NZ504026A (en) | Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C | |
HUS1300069I1 (hu) | Dextrometorfánt és kinidint tartalmazó gyógyászati készítmények neurológiai rendellenességek kezelésére | |
HK1084034A1 (en) | Eye-drop vaccine containing copolymer 1 for therapeutic immunization | |
WO2007046103A3 (en) | System for iontophoretic transdermal delivery of polymeric agents and methods of use thereof | |
NZ516477A (en) | Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders | |
WO2003103573A3 (en) | METHODS OF TREATING A NEUROLOGICAL DISORDER BY PERIPHERAL DELIVERY OF A TROPHIC FACTOR | |
ZA972601B (en) | Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer | |
WO2005094497A3 (en) | Systemic delivery of therapeutics to central nervous system | |
DE68906066D1 (de) | Peptid und dessen salze und antiallergische peptidmittel, welche diese peptide enthalten. | |
KR100488038B1 (ko) | 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도 | |
CA2465245A1 (en) | Biologically active peptides and their use for repairing injured nerves | |
胡军 et al. | COMPARISON ON THE CLINICAL EFFECT IN THE TREATMENT OF HYPERTHYROIDISM WITH DIFFERENT ACUPUNCTURE INTERVAL | |
ECSP982751A (es) | Uso de aminometil-cromanos sustituidos para el impedimento de la degeneracion neuronal y para el estimulo de la regeneracion neuronal | |
HK1056117A1 (en) | Treatment of hepatitis C with thymosin and pegylated interferon | |
NZ330758A (en) | Treatment of neural damage using GPE (the tripeptide gly-pro-glu) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed |